Skip to main content
Lori Leslie, MD, Oncology, Hackensack, NJ, Hackensack Meridian Health Hackensack University Medical Center

LoriAnnLeslieMD

Oncology • Hackensack, NJ

Hematologic Oncology

Lymphoma Attending, John Theurer Cancer Center -- Director, Indolent Lymphoma and CLL research programs -- Medical Co-Directory of Oncology, Mountainside Medical Center -- Assistant Professor of Medicine, Hackensack Meridian School of Medicine

Request Appointment

Overview of Dr. Leslie

As director of the Indolent Lymphoma and CLL Research Programs at John Theurer Cancer Center, I treat all types of lymphoma and work as part of a research team involved in numerous studies resulting in FDA-approved agents in B-cell disorders. These new therapies have helped launch an exciting new era in lymphoma treatment, with 60% of all lymphomas now being treatable.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2009

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2015 - 2025
  • TX State Medical License
    TX State Medical License 2012 - 2015
  • NY State Medical License
    NY State Medical License 2011 - 2013
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
    Lori A. Leslie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
    Lori A. Leslie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts Say
    CAR-T Destined for Earlier Lines of Therapy in Blood Cancers, Experts SayNovember 18th, 2022
  • EFS Improvement with Axi-Cel CAR-T a ‘Breakthrough’ in Second-Line Treatment of DLBCL
    EFS Improvement with Axi-Cel CAR-T a ‘Breakthrough’ in Second-Line Treatment of DLBCLDecember 11th, 2021
  • Understanding Lymphoma
    Understanding LymphomaJuly 19th, 2021
  • Join now to see all

Other Languages

  • Spanish

Hospital Affiliations

Dr. Lori Leslie, Dr. Lori Leslie, MD, Dr. L Leslie, Dr. Lori Ann Leslie